Key result
Post-ACS lipid-lowering therapy leaves ~48% of patients above the LDL-C goal at 6 weeks.
Why the study?
Patients after acute coronary syndrome are at very high risk for recurrent events, and real-life data on LDL-C target achievement and treatment adherence are needed to optimize secondary prevention.
Observational (n=524)
Yes
In a real-world Italian cohort of post-ACS patients, only about half achieved the LDL-C target of <70 mg/dL despite high rates of statin prescription, highlighting a gap in secondary prevention.
No takes yet. Share an insight, caveat, or question.
Suboptimal LDL-C target achievement persists after ACS in Italian real-world care; leaves open the need for improved implementation strategies.
Faggiano et al. (2020) conducted an observational in Acute coronary syndrome (n=524). Lipid lowering treatment (statin-based therapy) was evaluated on LDL-C target (<70 mg/dl) achievement at 6 weeks. Among patients with recent acute coronary syndrome receiving lipid-lowering therapy, only 51.7% achieved the LDL-C target of <70 mg/dl at 6 weeks and 45.8% at 18 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: